Darryl Toth

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 806 citations · Full text

Medicine, Dermatology, Pharmacotherapy +10

A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis

Mark Lebwohl, Stephen K. Tyring, Tiffani K. Hamilton et al. · New England Journal of Medicine · 2003 · 580 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

Kenneth B. Gordon, Richard G. Langley, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology · 2006 · 507 citations

Medicine, Dermatology, Immunology +10

Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

Kim Papp, Jacek C. Szepietowski, Leon Kircik et al. · Journal of the American Academy of Dermatology · 2021 · 297 citations

Medicine, Dermatology, Pharmacotherapy +16

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

Ulrich Mrowietz, Craig L. Leonardi, Giampiero Girolomoni et al. · Journal of the American Academy of Dermatology · 2015 · 206 citations

Medicine, Dermatology, Immunology +11